‘Ultrapotent’ antibodies neutralized SARS-CoV-2 variants in NIAID study

, , ,

On Jan. 20, 2022, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced that they had developed an array of monoclonal antibodies from recovered COVID-19 patients, and two of the therapeutic treatments in a recent study neutralized a variety of disease-causing virus variants.

The study, not peer reviewed but posted on medRxiv, showed that the monoclonal antibodies have モultrapotent neutralizing activityヤ against SARS-CoV-2, the virus that causes COVID-19.

Tags:


Source: medRxiv
Credit:

Advertise in our E-history sent to 5,000 plus company decision makers twice per month for only $300 per month. Reserve your space now! E-mail: info@LifeScienceHistory.com.